Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Shayan Owji, Stella A. Caldas, Benjamin Ungar

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Atopic dermatitis (AD) is a common chronic, pruritic inflammatory skin disease that profoundly impacts patients’ quality of life. As the first FDA-approved topical JAK inhibitor, ruxolitinib 1.5% cream represents a novel therapeutic topical agent for the treatment of AD. The objective of this review is to summarize the efficacy and safety of ruxolitinib cream in patients with AD based on the available evidence. Overall, ruxolitinib cream demonstrated high efficacy and a favorable safety profile for treating atopic dermatitis.

Original languageEnglish
Pages (from-to)1527-1537
Number of pages11
JournalJournal of Asthma and Allergy
StatePublished - 2022


  • JAK inhibitor
  • atopic dermatitis
  • eczema
  • itch
  • ruxolitinib
  • topical


Dive into the research topics of 'Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib'. Together they form a unique fingerprint.

Cite this